IP Library Granted Patent US 11,345,653
Granted Patent B2
US 11,345,653 · App. 16/310,686 · Granted May 31, 2022

Compositions and methods for reactivating cholinesterases

Inventors: Ilja Khavrutskii (Brunswick, MD); Sven Anders Wallqvist (Frederick, MD)
Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.; The Government of the United States as Represented by the Secretary of the Army
C07C215/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,345,653
App. No.
16/310,686
Granted
May 31, 2022
Kind
B2
Abstract

The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.

Claims (30)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein

is a 5- or 6-membered substituted or unsubstituted aromatic ring or a 5- or 6-membered substituted or unsubstituted cycloalkyl;

R 1 is R 5 —C(R 6 )(OH)—R 7 —C(R 8 )(NH 2 )—R 9 ;

R 2 is NH 2 ;

R 3 is NH 2 ; wherein R 3 is ortho to R 1 and R 1 is ortho to R 2 ;

R 4 is selected from the group consisting of H, CN, OR 10 , S(O) 0-2 R 10 , C 1-6 alkyl, C 1-6 alkene, NR 11 R 12 and C(O)NR 13 R 14 ;

R 5 is selected from the group consisting of a bond, C 1-4 alkylene and C 1-4 alkenylene;

R 6 is selected from the group consisting of H and C 1-3 alkyl;

R 7 is selected from the group consisting of a bond, substituted or unsubstituted C 1-3 alkylene and substituted or unsubstituted C 1-3 alkenylene;

R 8 is selected from the group consisting of H, C(O)NHR 15 and C(O)OR 15 ;

R 9 is selected from the group consisting of H, CN, —C(R 6 ) 2 OH, OR 8 , NR 11 R 12 , C(O)NR 11 R 12 , C 1-6 alkyl and C 1-6 alkene;

R 10 is selected from the group consisting of H, C 1-3 alkyl and C 6-12 aryl;

R 11 , R 12 , R 13 , and R 14 are independently selected from the group consisting of H, C 1-4 alkyl and C 1-4 alkene, wherein at least one of R 11 and R 12 is H; and

R 15 is selected from the group consisting of H and C 1-3 alkyl.

2. A compound selected from:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein the compound is

4. A method of reactivating an inactivated acetylcholinesterase (AChE) or preventing inactivation of an AChE in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I of claim 1 , or a pharmaceutically acceptable salt thereof.

5. A method of reactivating an inactivated acetylcholinesterase (AChE) or preventing inactivation of an AChE in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein the compound is

7. The method of claim 4 , wherein the method is directed to reactivating an inactivated AChE and the inactivated AChE is an aged AChE.

8. The method of claim 4 , wherein the method is directed to preventing inactivation of an AChE and the subject was exposed to an inactivating agent.

9. The method of claim 8 , wherein the compound of Formula I is co-administered with an oxime.

10. The method of claim 8 , wherein the subject was exposed to sarin, soman or cyclosarin prior to administration of the compound of Formula I.

11. The method of claim 5 , wherein the method is directed to reactivating an inactivated AChE and the inactivated AChE is an aged AChE.

12. The method of claim 5 , wherein the method is directed to preventing inactivation of an AChE and the subject was exposed to an inactivating agent.

13. The method of claim 12 , wherein the compound is co-administered with an oxime.

14. The method of claim 12 , wherein the subject was exposed to sarin, soman or cyclosarin prior to administration of the compound.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2021
From: KHAVRUTSKII, ILJA
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 055973/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2021
From: WALLQVIST, SVEN ANDERS
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 055891/0594 →
CONFIRMATORY LICENSE Recorded Nov 15, 2019
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 051026/0844 →
Continuity (2)
Provisional Application 62351384 · Jun 17, 2016
Related Publication 20190345097A1 · Nov 14, 2019